vs
Side-by-side financial comparison of Intel (INTC) and Medtronic (MDT). Click either name above to swap in a different company.
Intel is the larger business by last-quarter revenue ($13.6B vs $9.0B, roughly 1.5× Medtronic). Medtronic runs the higher net margin — 15.3% vs -6.5%, a 21.9% gap on every dollar of revenue. On growth, Intel posted the faster year-over-year revenue change (7.0% vs 6.6%). Medtronic produced more free cash flow last quarter ($457.0M vs $-2.0B). Over the past eight quarters, Medtronic's revenue compounded faster (5.3% CAGR vs 2.9%).
Intel Corporation is an American multinational technology company headquartered in Santa Clara, California. It designs, manufactures, and sells computer components such as central processing units (CPUs) and related products for business and consumer markets. Intel was the world's third-largest semiconductor chip manufacturer by revenue in 2024 and has been included in the Fortune 500 list of the largest United States corporations by revenue since 2007.
Medtronic plc is an Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.
INTC vs MDT — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.6B | $9.0B |
| Net Profit | $-887.0M | $1.4B |
| Gross Margin | 34.4% | 65.8% |
| Operating Margin | — | 18.8% |
| Net Margin | -6.5% | 15.3% |
| Revenue YoY | 7.0% | 6.6% |
| Net Profit YoY | -382.6% | 8.2% |
| EPS (diluted) | $-0.73 | $1.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $13.6B | — | ||
| Q4 25 | $13.7B | $9.0B | ||
| Q3 25 | $13.7B | $8.6B | ||
| Q2 25 | $12.9B | $8.9B | ||
| Q1 25 | $12.7B | $8.3B | ||
| Q4 24 | $14.3B | $8.4B | ||
| Q3 24 | $13.3B | $7.9B | ||
| Q2 24 | $12.8B | $8.6B |
| Q1 26 | $-887.0M | — | ||
| Q4 25 | $-591.0M | $1.4B | ||
| Q3 25 | $4.1B | $1.0B | ||
| Q2 25 | $-2.9B | $1.1B | ||
| Q1 25 | $-821.0M | $1.3B | ||
| Q4 24 | $-126.0M | $1.3B | ||
| Q3 24 | $-16.6B | $1.0B | ||
| Q2 24 | $-1.6B | $654.0M |
| Q1 26 | 34.4% | — | ||
| Q4 25 | 36.1% | 65.8% | ||
| Q3 25 | 38.2% | 65.0% | ||
| Q2 25 | 27.5% | 64.8% | ||
| Q1 25 | 36.9% | 66.5% | ||
| Q4 24 | 39.2% | 64.9% | ||
| Q3 24 | 15.0% | 65.1% | ||
| Q2 24 | 35.4% | 64.5% |
| Q1 26 | — | — | ||
| Q4 25 | 4.2% | 18.8% | ||
| Q3 25 | 5.0% | 16.8% | ||
| Q2 25 | -24.7% | 16.1% | ||
| Q1 25 | -2.4% | 19.9% | ||
| Q4 24 | 2.9% | 19.0% | ||
| Q3 24 | -68.2% | 16.1% | ||
| Q2 24 | -15.3% | 12.3% |
| Q1 26 | -6.5% | — | ||
| Q4 25 | -4.3% | 15.3% | ||
| Q3 25 | 29.8% | 12.1% | ||
| Q2 25 | -22.7% | 11.8% | ||
| Q1 25 | -6.5% | 15.6% | ||
| Q4 24 | -0.9% | 15.1% | ||
| Q3 24 | -125.3% | 13.2% | ||
| Q2 24 | -12.5% | 7.6% |
| Q1 26 | $-0.73 | — | ||
| Q4 25 | $-0.10 | $1.07 | ||
| Q3 25 | $0.90 | $0.81 | ||
| Q2 25 | $-0.67 | $0.81 | ||
| Q1 25 | $-0.19 | $1.01 | ||
| Q4 24 | $-0.03 | $0.99 | ||
| Q3 24 | $-3.88 | $0.80 | ||
| Q2 24 | $-0.38 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $32.8B | $8.3B |
| Total DebtLower is stronger | $2.0B | $27.7B |
| Stockholders' EquityBook value | $125.0B | $48.7B |
| Total Assets | $205.3B | $91.3B |
| Debt / EquityLower = less leverage | 0.02× | 0.57× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $32.8B | — | ||
| Q4 25 | $14.3B | $8.3B | ||
| Q3 25 | $11.1B | $8.1B | ||
| Q2 25 | $9.6B | $9.0B | ||
| Q1 25 | — | $7.9B | ||
| Q4 24 | $8.2B | $8.0B | ||
| Q3 24 | — | $7.8B | ||
| Q2 24 | — | $8.0B |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $46.6B | $27.7B | ||
| Q3 25 | — | $26.2B | ||
| Q2 25 | — | $25.6B | ||
| Q1 25 | — | $24.0B | ||
| Q4 24 | $50.0B | $24.6B | ||
| Q3 24 | — | $26.3B | ||
| Q2 24 | — | $23.9B |
| Q1 26 | $125.0B | — | ||
| Q4 25 | $114.3B | $48.7B | ||
| Q3 25 | $106.4B | $47.9B | ||
| Q2 25 | $97.9B | $48.0B | ||
| Q1 25 | $99.8B | $49.4B | ||
| Q4 24 | $99.3B | $48.5B | ||
| Q3 24 | $99.5B | $47.9B | ||
| Q2 24 | $115.2B | $50.2B |
| Q1 26 | $205.3B | — | ||
| Q4 25 | $211.4B | $91.3B | ||
| Q3 25 | $204.5B | $91.0B | ||
| Q2 25 | $192.5B | $91.7B | ||
| Q1 25 | $192.2B | $90.0B | ||
| Q4 24 | $196.5B | $90.0B | ||
| Q3 24 | $193.5B | $89.7B | ||
| Q2 24 | $206.2B | $90.0B |
| Q1 26 | 0.02× | — | ||
| Q4 25 | 0.41× | 0.57× | ||
| Q3 25 | — | 0.55× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | 0.50× | 0.51× | ||
| Q3 24 | — | 0.55× | ||
| Q2 24 | — | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $925.0M |
| Free Cash FlowOCF − Capex | $-2.0B | $457.0M |
| FCF MarginFCF / Revenue | -14.8% | 5.1% |
| Capex IntensityCapex / Revenue | 36.6% | 5.2% |
| Cash ConversionOCF / Net Profit | — | 0.67× |
| TTM Free Cash FlowTrailing 4 quarters | $-2.6B | $5.2B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.3B | $925.0M | ||
| Q3 25 | $2.5B | $1.1B | ||
| Q2 25 | $2.0B | $2.5B | ||
| Q1 25 | $813.0M | $2.6B | ||
| Q4 24 | $3.2B | $958.0M | ||
| Q3 24 | $4.1B | $986.0M | ||
| Q2 24 | $2.3B | $2.8B |
| Q1 26 | $-2.0B | — | ||
| Q4 25 | $800.0M | $457.0M | ||
| Q3 25 | $121.0M | $584.0M | ||
| Q2 25 | $-1.5B | $2.1B | ||
| Q1 25 | $-4.4B | $2.1B | ||
| Q4 24 | $-2.7B | $554.0M | ||
| Q3 24 | $-2.4B | $466.0M | ||
| Q2 24 | $-3.4B | $2.4B |
| Q1 26 | -14.8% | — | ||
| Q4 25 | 5.9% | 5.1% | ||
| Q3 25 | 0.9% | 6.8% | ||
| Q2 25 | -11.7% | 23.2% | ||
| Q1 25 | -34.5% | 25.3% | ||
| Q4 24 | -18.7% | 6.6% | ||
| Q3 24 | -18.1% | 5.9% | ||
| Q2 24 | -26.4% | 27.4% |
| Q1 26 | 36.6% | — | ||
| Q4 25 | 25.5% | 5.2% | ||
| Q3 25 | 17.8% | 5.9% | ||
| Q2 25 | 27.6% | 5.1% | ||
| Q1 25 | 40.9% | 5.7% | ||
| Q4 24 | 40.9% | 4.8% | ||
| Q3 24 | 48.6% | 6.6% | ||
| Q2 24 | 44.3% | 5.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.67× | ||
| Q3 25 | 0.63× | 1.05× | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | — | 1.99× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | 0.95× | ||
| Q2 24 | — | 4.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INTC
| Intel Products | $12.8B | 94% |
| All other | $600.0M | 4% |
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
